Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director · President, R&D · 10% owner | September 04, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date September 04, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,302,145 |
Ending reported balance
After 2026-09-04 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2026-09-04 · Sale · Disposed 520 · Balance 1,326,625 F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 2 · 2026-09-04 · Sale · Disposed 2,006 · Balance 1,324,619 F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 3 · 2026-09-04 · Sale · Disposed 3,267 · Balance 1,321,352 F5: The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 4 · 2026-09-04 · Sale · Disposed 3,962 · Balance 1,317,390 F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 5 · 2026-09-04 · Sale · Disposed 3,180 · Balance 1,314,210 F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 6 · 2026-09-04 · Sale · Disposed 3,392 · Balance 1,310,818 F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 7 · 2026-09-04 · Sale · Disposed 2,320 · Balance 1,308,498 F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 8 · 2026-09-04 · Sale · Disposed 1,242 · Balance 1,307,256 F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 9 · 2026-09-04 · Sale · Disposed 1,992 · Balance 1,305,264 F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 10 · 2026-09-04 · Sale · Disposed 565 · Balance 1,304,699 F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 11 · 2026-09-04 · Sale · Disposed 1,329 · Balance 1,303,370 F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 12 · 2026-09-04 · Sale · Disposed 826 · Balance 1,302,544 F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 13 · 2026-09-04 · Sale · Disposed 399 · Balance 1,302,145 F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Spousal Trust | 90,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 90,000 F16: Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Suma Mani Krishnan Trust | 51,010 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 51,010 F17: Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Family Trust | 50,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 50,000 F18: Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5: The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F16: Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee.
F17: Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust.
F18: Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2020 Filed Sep 17, 2020 22:35 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,142 | $46.85 | $240,895.50 |
DisclosureSEC source: 0000899243-20-025576 · doc4.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,855,221 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. The Rule 10b5-1 trading plan has now expired. F5 · price: This transaction was executed in multiple trades ranging from $46.64 to $47.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 22:35 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 9,749 | $46.24 | $450,821.06 |
DisclosureSEC source: 0000899243-20-025576 · doc4.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,860,363 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. The Rule 10b5-1 trading plan has now expired. F4 · price: This transaction was executed in multiple trades ranging from $45.64 to $46.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 22:35 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,517 | $47.15 | $71,523.21 |
DisclosureSEC source: 0000899243-20-025576 · doc4.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,870,112 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. The Rule 10b5-1 trading plan has now expired. F3 · price: This transaction was executed in multiple trades ranging from $46.76 to $47.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 22:35 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 14,435 | $46.21 | $667,031.25 |
DisclosureSEC source: 0000899243-20-025576 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,871,629 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. The Rule 10b5-1 trading plan has now expired. F2 · price: This transaction was executed in multiple trades ranging from $45.76 to $46.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 11,719 | $45.07 | $528,182.36 |
DisclosureSEC source: 0000899243-20-016834 · doc4.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886,064 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F6 · price: This transaction was executed in multiple trades ranging from $44.91 to $45.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 11,311 | $44.56 | $504,057.75 |
DisclosureSEC source: 0000899243-20-016834 · doc4.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,897,783 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F5 · price: This transaction was executed in multiple trades ranging from $43.91 to $44.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,740 | $43.21 | $464,070.03 |
DisclosureSEC source: 0000899243-20-016834 · doc4.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,909,094 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F4 · price: This transaction was executed in multiple trades ranging from $42.85 to $43.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 8,652 | $42.24 | $365,426.74 |
DisclosureSEC source: 0000899243-20-016834 · doc4.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,919,834 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F3 · price: This transaction was executed in multiple trades ranging from $41.84 to $42.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 7,578 | $41.31 | $313,038.09 |
DisclosureSEC source: 0000899243-20-016834 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,928,486 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F2 · price: This transaction was executed in multiple trades ranging from $40.84 to $41.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 00:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 659 | $40.20 | $26,492.99 |
DisclosureSEC source: 0001209191-20-020124 · doc4.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936,064 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F5 · price: This transaction was executed in multiple trades ranging from $40.00 to $40.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 00:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4 | $42.03 | $168.12 |
DisclosureSEC source: 0001209191-20-020124 · doc4.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936,723 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 00:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,396 | $41.27 | $57,607.06 |
DisclosureSEC source: 0001209191-20-020124 · doc4.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936,727 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F4 · price: This transaction was executed in multiple trades ranging from $41.00 to $41.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 00:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,780 | $40.49 | $436,429.38 |
DisclosureSEC source: 0001209191-20-020124 · doc4.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,938,123 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F3 · price: This transaction was executed in multiple trades ranging from $40.00 to $40.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 16, 2020 Filed Mar 19, 2020 00:14 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,559 | $40.14 | $102,714.17 |
DisclosureSEC source: 0001209191-20-020124 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,948,903 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F2 · price: This transaction was executed in multiple trades ranging from $40.00 to $40.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 18, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 239 | $63.31 | $15,132.12 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 14 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,951,462 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F15 · price: This transaction was executed in multiple trades ranging from $63.08 to $63.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 18, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,756 | $62.65 | $360,592.10 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 13 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,951,701 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F14 · price: This transaction was executed in multiple trades ranging from $62.07 to $63.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 18, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 900 | $61.28 | $55,152.99 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 12 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,957,457 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F13 · price: This transaction was executed in multiple trades ranging from $61.00 to $61.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 18, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,017 | $60.19 | $61,215.37 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 11 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,958,357 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F12 · price: This transaction was executed in multiple trades ranging from $59.89 to $60.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 18, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,200 | $59.49 | $71,387.16 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,959,374 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F11 · price: This transaction was executed in multiple trades ranging from $58.84 to $59.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 279 | $63.35 | $17,673.87 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960,574 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F10 · price: This transaction was executed in multiple trades ranging from $63.34 to $63.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,834 | $62.79 | $115,158.14 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,960,853 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F9 · price: This transaction was executed in multiple trades ranging from $62.20 to $63.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 891 | $61.72 | $54,994.48 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,962,687 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F8 · price: This transaction was executed in multiple trades ranging from $61.16 to $62.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 8,799 | $60.46 | $531,996.34 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,963,578 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F7 · price: This transaction was executed in multiple trades ranging from $60.14 to $61.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 8,138 | $59.87 | $487,202.53 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,972,377 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F6 · price: This transaction was executed in multiple trades ranging from $59.14 to $60.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 322 | $65.60 | $21,124.55 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,980,515 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F5 · price: This transaction was executed in multiple trades ranging from $65.19 to $65.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,856 | $64.28 | $376,413.14 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,980,837 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F4 · price: This transaction was executed in multiple trades ranging from $64.10 to $65.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 7,396 | $63.62 | $470,559.41 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,986,693 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F3 · price: This transaction was executed in multiple trades ranging from $63.10 to $64.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 7,373 | $62.84 | $463,351.76 |
DisclosureSEC source: 0001209191-19-061173 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,994,089 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person following discussions with the Compensation Committee and the Board of Directors. F2 · price: This transaction was executed in multiple trades ranging from $62.08 to $63.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 21:28 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | PurchaseCommon Stock | 25,000 | $20.00 | $500,000.00 |
DisclosureSEC source: 0001209191-18-055882 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,001,462 Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | PurchaseCommon Stock | 1,018 | $12.45 | $12,674.10 |
DisclosureSEC source: 0001209191-18-036328 · doc4.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,976,462 F3 · price: This transaction was executed in multiple trades ranging from $12.11 to $12.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | PurchaseCommon Stock | 13,116 | $11.15 | $146,177.82 |
DisclosureSEC source: 0001209191-18-036328 · doc4.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,975,444 F2 · price: This transaction was executed in multiple trades ranging from $11.10 to $12.00. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:08 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | PurchaseCommon Stock | 10,866 | $10.75 | $116,757.34 |
DisclosureSEC source: 0001209191-18-036328 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,962,328 F1 · price: This transaction was executed in multiple trades ranging from $10.73 to $11.00. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:01 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | OtherCommon Stock | 16,213 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-035583 · doc4.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,951,462 F1 · shares: Award of restricted stock. F1 · price: Award of restricted stock. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:25 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | ConversionSeries A Convertible Preferred Stock · Derivative | 112,162 | $0.00 | $0.00 |
DisclosureSEC source: 0000925421-17-000361 · edgar.xml · derivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 0 Underlying: Common Stock · 112,162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.exercise_date: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F1 · derivative.expiration_date: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F2 · ownership.nature: Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:25 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | ConversionCommon Stock | 112,162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000925421-17-000361 · edgar.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 112,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A convertible preferred stock converted on a one-to-one basis into 112,162 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering. F2 · ownership.nature: Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. Read SEC document |
| September 22, 2017 Filed Sep 25, 2017 21:25 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | PurchaseCommon Stock | 100,000 | $10.00 | $1,000,000.00 |
DisclosureSEC source: 0000925421-17-000361 · edgar.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · Chief Operating Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,935,249 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.